Loading...
Thumbnail Image
Publication

VentX promotes tumor specific immunity and efficacy of immune checkpoint inhibitors

Le, Yi
Gao, Hong
Le, Joanna
Hornick, Jason L
Bleday, Ronald
Wee, Jon
Zhu, Zhenglun
Citations
Google Scholar:
Altmetric:
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Journal Article
Publication Date
2023-12-14
Subject Area
Embargo Expiration Date
Abstract

Immune suppression within tumor microenvironments (TME) have been implicated in limited efficacy of immune check point inhibitors (ICIs) against solid tumors. Down-regulated VentX expression in tumor associated macrophages (TAMs) underlies phagocytotic anergic phenotype of TAMs, which govern immunological state of TME. In this study, using a tumor immune microenvironment enabling model system (TIME-EMS) of non-small cell lung cancer (NSCLC), we found that PD-1 antibody modestly activates cytotoxic T lymphocytes (CTLs) within the NSCLC-TME but not the status of TIME. We showed that the restoration of VentX expression in TAMs reignites the phagocytotic function of TAMs, which in turn, transforms TIME, activates CTLs in a tumor-specific manner and promotes efficacy of PD-1 antibody against NSCLC but not toxicity on normal lung epithelial cells. Supported by data on NSG-PDX models of primary human NSCLC, our study revealed potential venues to promote the efficacy of ICI against solid tumors through VentX-based mechanisms.

Source

Le Y, Gao H, Le J, Hornick JL, Bleday R, Wee J, Zhu Z. VentX promotes tumor specific immunity and efficacy of immune checkpoint inhibitors. iScience. 2023 Dec 14;27(1):108731. doi: 10.1016/j.isci.2023.108731. PMID: 38299030; PMCID: PMC10829883.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1016/j.isci.2023.108731
PubMed ID
38299030
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Copyright 2023 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).